Top 5 Articles of the Week: January 12-17

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

1. Reflecting on the Growth of NPs and PAs in Dermatology

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, a dermatology nurse practitioner at the Veterans Affairs Portland Health Care System in Oregon, shared her reflections on the transformative experience of being a co-chair of the Horizons in Advanced Practice meeting, a conference dedicated to advancing the knowledge and skills of dermatology nurse practitioners (NPs) and physician assistants (PAs).

2. ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment

Eirion Therapeutics announced positive results for its first-in-man clinical trial of pharmaceutical, small molecule ET-02 in the treatment of androgenic alopecia.1 The topical therapy was safe and well-tolerated, with results being observed in as early as 5 weeks.

3. Dermatology Conferences and Meetings Calendar: 2025

Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025. Using these responses, we have compiled a list of dermatological meetings taking place this year.

4. DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management

The FDA approval in November 2024 of 40-mg minocycline hydrochloride (Emrosi; Journey Medical Corporation), formerly known and hereafter referred to as DFD-29, marked a significant step forward in the treatment of rosacea.

The approval of these 40-mg extended-release capsules represents the first time an oral, systemic therapy has been given the green light in the US to address both erythema and inflammatory lesions—2 hallmark symptoms of rosacea. Here, Dermatology Times looks back at DFD-29’s journey to approval and its future role in the rosacea treatment landscape.

5. The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia

Eirion Therapeutics announced positive results for its first-in-man clinical trial of topical ET-02 in the treatment of androgenic alopecia. The drug was safe and well-tolerated, with unprecedented results being observed as early as 5 weeks.

Dermatology Times spoke with Jon Edelson, MD, CEO and President of Eirion. He shared groundbreaking insights into the therapeutic potential of ET-02, its mechanism of action, and how it aims to revolutionize the treatment landscape for hair loss.